McWhirter E - Search Results

1

Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use.

Li Y, Pond G, McWhirter E. Li Y, et al. Among authors: mcwhirter e. Curr Oncol. 2024 Jan 11;31(1):425-435. doi: 10.3390/curroncol31010028. Curr Oncol. 2024. PMID: 38248113 Free PMC article.

2

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.

McWhirter E, Quirt I, Gajewski T, Pond G, Wang L, Hui J, Oza A. McWhirter E, et al. Invest New Drugs. 2016 Apr;34(2):231-5. doi: 10.1007/s10637-016-0324-0. Epub 2016 Feb 3. Invest New Drugs. 2016. PMID: 26841902 Clinical Trial.

3

Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?

Pitre LD, Linford G, Pond GR, McWhirter E, Seow H. Pitre LD, et al. Among authors: mcwhirter e. J Cutan Med Surg. 2019 Nov/Dec;23(6):586-594. doi: 10.1177/1203475419870177. Epub 2019 Aug 28. J Cutan Med Surg. 2019. PMID: 31462069

4

Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

Petrella TM, Fletcher GG, Knight G, McWhirter E, Rajagopal S, Song X, Baetz TD. Petrella TM, et al. Among authors: mcwhirter e. Curr Oncol. 2020 Feb;27(1):e43-e52. doi: 10.3747/co.27.5933. Epub 2020 Feb 1. Curr Oncol. 2020. PMID: 32218667 Free PMC article.

5

Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.

Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage KJ, Skinn B, Romeyer F, Smylie M. Hogg D, et al. Among authors: mcwhirter e. Curr Oncol. 2020 Aug;27(4):204-214. doi: 10.3747/co.27.5985. Epub 2020 Aug 1. Curr Oncol. 2020. PMID: 32905202 Free PMC article.

6

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.

Chan SWS, Shukla R, Ramsay J, McWhirter E, Barnfield P, Juergens RA. Chan SWS, et al. Among authors: mcwhirter e. Curr Oncol. 2023 Apr 27;30(5):4527-4537. doi: 10.3390/curroncol30050342. Curr Oncol. 2023. PMID: 37232800 Free PMC article.

7

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.

Barron CC, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, McWhirter E. Barron CC, et al. Among authors: mcwhirter e. J Immunother Cancer. 2023 Aug;11(8):e006500. doi: 10.1136/jitc-2022-006500. J Immunother Cancer. 2023. PMID: 37536939 Free PMC article. Review.

8

Pembrolizumab-induced immune-related sclerosing cholangitis.

Li Y, Stewart L, Tang S, McWhirter E. Li Y, et al. Among authors: mcwhirter e. BMJ Case Rep. 2023 Nov 1;16(11):e256125. doi: 10.1136/bcr-2023-256125. BMJ Case Rep. 2023. PMID: 37914171

9

Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review.

Rajagopal S, Yao X, Abadir W, Baetz TD, Easson A, Knight G, McWhirter E, Nessim C, Rosen CF, Sun A, Wright FC, Petrella TM. Rajagopal S, et al. Among authors: mcwhirter e. Surg Oncol. 2024 Jun;54:102077. doi: 10.1016/j.suronc.2024.102077. Epub 2024 Apr 10. Surg Oncol. 2024. PMID: 38657486 Free article. Review.

10

Update on Immunotherapeutics in the Management of Metastatic Melanoma.

Bulir D, Liang S, O’Malley M, McWhirter E. Bulir D, et al. Among authors: mcwhirter e. Skin Therapy Lett. 2019 Jan;24(1):8-11. Skin Therapy Lett. 2019. PMID: 30817881 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters